CD274 and classic Hodgkin lymphoma: The inclusion of anti-PD-L1 mAb into the treatment armamentarium of cHL has provided patients with R/R disease who are insensitive to cytotoxic chemotherapy with the potential for long-term remission, particularly in those achieving deep response to treatment.